Everything tagged "specialty business services" across research, earnings, and macro.
2 articles
Copart remains a high-quality compounder with elite margins, a fortress balance sheet, and durable international growth levers. Near-term revenue growth has slowed, but the stock still screens as a Buy on valuation and cash generation.
Aramark is gaining momentum with strong contract retention, double-digit organic growth, and improving cash generation. The stock looks more attractive on forward earnings than trailing results, with Aramark Nexus adding a new growth lane.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator